mutations and sophisticated kar yotype. It follows a linear evolution through the CLL clone with the recurrent acquisition of CDKN2ANot all patients with CLL demand therapy. Despite all the latest innovations, the iwCLL continue to recommends watchful observation for individuals with asymptomatic disease.86 This recommendation is predicated on at l